异丙基-(1,1,3,3-四甲基-丁基)-胺 | 51609-07-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 异丙基-(1,1,3,3-四甲基-丁基)-胺
• 英文名称: isopropyl-(1,1,3,3-tetramethyl-butyl)-amine
• 英文别名: Isopropyl-(1,1,3,3-tetramethyl-butyl)-amin；2-Isopropylamino-2,4,4-trimethyl-pentan；2,4,4-Trimethyl-2-pentyl-isopropylamin；2,4,4-Trimethyl-2-pentylisopropylamin；2,4,4-trimethyl-N-propan-2-ylpentan-2-amine
• CAS: 51609-07-5
• 化学式: C₁₁H₂₅N
• 分子量: 171.326
• InChiKey: AFVHTMKOEBCJIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  异丙基-(1,1,3,3-四甲基-丁基)-胺 、 2,6-二甲苯基异氰酸酯 在 苯甲醚 作用下， 生成 N-2,6-Dimethylphenyl-N'-2,4,4-trimethyl-2-pentyl,N'-isopropylharnstoff
  参考文献：
  名称：

  Urea dissociation. Measure of steric hindrance in secondary amines

  摘要：

  DOI：

  10.1021/jo00930a039
• 作为产物：
  描述：

  叔辛胺 、 2-溴丙烷 生成 异丙基-(1,1,3,3-四甲基-丁基)-胺
  参考文献：
  名称：

  t-Carbinamines, RR'R”CNH₂. I. Reaction with Alkyl Halides and Alkylene Oxides¹

  摘要：

  DOI：

  10.1021/ja01597a048

文献信息

• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• [EN] IMMUNOMODULATOR COMPOUNDS<br/>[FR] COMPOSÉS IMMUNOMODULATEURS
  申请人：CHEMOCENTRYX INC

  公开号：WO2019023575A1

  公开（公告）日：2019-01-31

  Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  提供了作为免疫调节剂有用的化合物。这些化合物具有以下的化学式（I），包括其立体异构体和药用盐，其中Z、L、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R3、R4、R5、R6a、R6b、m和n的定义如本文所述。还公开了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• [EN] METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER AVEC DES INHIBITEURS DE PD-L1 À PETITES MOLÉCULES
  申请人：CHEMOCENTRYX INC

  公开号：WO2020047035A1

  公开（公告）日：2020-03-05

  The present disclosure provides, inter alia, methods of treating cancer by administering an effective amount of a compound of Formula (I). In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is melanoma. In some aspects, the present disclosure provides methods of increasing the CD8+ T cell/CD4+ T cell ratio in a solid tumor microenvironment by administering an effective amount of a compound of Formula (I).

  本公开提供了治疗癌症的方法，其中包括通过给予化合物Formula (I)的有效剂量来治疗癌症。在某些实施例中，癌症是实体癌。在某些实施例中，癌症是黑色素瘤。在某些方面，本公开提供了通过给予化合物Formula (I)的有效剂量来增加实体肿瘤微环境中CD8+ T细胞/CD4+ T细胞比率的方法。
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。
• COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE
  申请人：CERULEAN PHARMA INC

  公开号：US20130059816A1

  公开（公告）日：2013-03-07

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了使用CDP-治疗剂共轭物治疗自身免疫性疾病、炎症性疾病或癌症的方法。还提供了CDP-治疗剂共轭物、包含CDP-治疗剂共轭物的粒子和包含CDP-治疗剂共轭物的组合物。